Products & Services · Total revenues

Excluding Comirnaty and Paxlovid — Total revenues

Pfizer Excluding Comirnaty and Paxlovid — Total revenues remained flat by 0.0% to $13.62B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.1%, from $12.83B to $13.62B. Over 3 years (FY 2022 to FY 2025), Excluding Comirnaty and Paxlovid — Total revenues shows an upward trend with a 8.1% CAGR.

Analysis

StatementSegment
First reportedQ1 2022
Last reportedQ4 2025Feb 26, 2026
Rolls up toTotal Revenue
Metric ID: pfe_segment_excluding_comirnaty_and_paxlovid_total_revenues

Historical Data

4 years
 FY'22FY'23FY'24FY'25
Value$43.08B$45.74B$51.33B$54.47B
YoY Change—+6.2%+12.2%+6.1%
Range$43.08B – $54.47B
CAGR+8.1%
Avg YoY Growth+8.2%
Median YoY Growth+6.2%
Current Streak3+ years growth

Frequently Asked Questions

What is Pfizer's excluding comirnaty and paxlovid — total revenues?
Pfizer (PFE) reported excluding comirnaty and paxlovid — total revenues of $13.62B in Q4 2025.
How has Pfizer's excluding comirnaty and paxlovid — total revenues changed year-over-year?
Pfizer's excluding comirnaty and paxlovid — total revenues increased by 6.1% year-over-year, from $12.83B to $13.62B.
What is the long-term trend for Pfizer's excluding comirnaty and paxlovid — total revenues?
Over 3 years (2022 to 2025), Pfizer's excluding comirnaty and paxlovid — total revenues has grown at a 8.1% compound annual growth rate (CAGR), from $43.08B to $54.47B.